Strategies aimed at attenuating the biological activity of BLyS are justified, given the presence of increased levels of endogenous BLyS in the circulation of MRL/lpr mice [11], as well as the frequently observed elevation of BLyS in RA and SLE patients [5,6,31]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.